TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Frequency of overall electrocardiographic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of proliferating (Ki67+) lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Abdominal pain score on the VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of uncovered struts at 12-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: balance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: directional control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: phonological skills performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MADRS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet count ≥ 50×10(9)/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Partial CO(2) pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time spent in the BIS interval (40-60)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of propofol needed for induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uncomfortable erythemas
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced fractional anisotropy (FA) in white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement of A1c treatment goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimum oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of hypoxaemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Moderate-to-severe exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hours of outdoor physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteraemias
Endpoint domain: Adverse events/effects
Primary endpoint: Survival at 48 hours post burn injury
Endpoint domain: Mortality/survival
Primary endpoint: Average urine output during the first 24 hours post burn injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival rate of the tested posts
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive function deterioration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of drugs prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improved neurological function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of postoperative pain
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of swelling
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of baicalein
Endpoint domain: Adverse events/effects
Primary endpoint: Bioequivalence of nateglinide formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum sodium level maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevention of excess sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevention of hyponatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SF-36 social function
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: SIS strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barthel score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time of recovery of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in very low-density lipoprotein cholesterol (VLDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in non-high-density lipoprotein cholesterol (non-HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to resolution of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Extraction fraction (E) for lymphoscintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: LE Ashworth score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: UE Ashworth score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: motor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion of anti-HBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: High-level response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bladder function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work-DASH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of CDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of CDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality due to CDD
Endpoint domain: Mortality/survival
Primary endpoint: self-reported binge drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported drinks per drinking day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean proportion of participants reporting a weekend binge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-benefit ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-management skills and abilities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: health-related quality of life (HRQoL) change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cesarean rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean randomization-to-delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ODC activity of at least 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of DFMO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of DFMO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperactivity/noncompliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial response rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: leg pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nursing skills performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMPS motor scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMPS process scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychological symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: availability of vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: offering fruits and vegetables for snacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in activities of daily living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mealtime conflict
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: infant autonomy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: infant weight maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder-tip pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of oral analgesics used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: rapid shallow breathing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: tracheal occlusion pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bowel function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in AHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean plasma triglyceride reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Well-tolerance of probiotic instillation
Endpoint domain: Adverse events/effects
Primary endpoint: Energy density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum lipoprotein(a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibro-fatty plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Necrotic core progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse events at 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Persistent plaque change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Intermediate plaques change at nonstented sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: serious suicide attempt
Endpoint domain: Mortality/survival
Primary endpoint: bipolar illness-related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doppler echocardiography-derived mean pressure gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Doppler echocardiography-derived maximal pressure gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate at month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delayed heart/mediastinum count ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Washout rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma NT-proBNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTcF change from time‐matched baseline (DeltaQTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of adverse bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration‐time curve from 0 to 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Weight regain during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in Gd-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in T2w lesion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in T1w hypointense lesion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post operation LVOTGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: inflammatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Probability of survival for rectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Pulmonary artery diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arteriolar resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Force oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of contralateral limb forces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in uptake between normal trabecula and BME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences among BME, BMH, and TMF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: waist perimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UI symptom improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete transit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mammogram screening rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IOP at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Cumulative failure rate at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean glaucoma medication use at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIS-LL responder analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in TQOL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BMI z score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Waist-circumference z score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean infant birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of microchimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity scores
Endpoint domain: Adverse events/effects
Primary endpoint: median hospital length of stay (LoS)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: percentage of cocaine positive urines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of self-reported days of cocaine abstinence
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Apgar score < 7 at 1 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neonatal outcomes
Primary endpoint: 6-minute walk distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum voluntary ventilation (MVV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Resistance Index (RI) of uterine arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Endometrial perfusion alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Functional state of the reproductive organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Patient's tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital signs stability (blood pressure, heart rate, pulse oxygen saturation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectacle wear compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: percent volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Snack-eating frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion in joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morning PEFR improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of low cardiac output syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to onset of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Global success (alive, clinically stable, radiographically improved)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increased mammographic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased (99m)Tc-sestamibi scintimammographic uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall colon cleansing efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in percentages of CD3+ T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in CCR6 expression in CD8+CD25+ and CD8+CD25+bright T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in CCR5 expression in CD3+ T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bacteria counts
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to open-ended questions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tendency to provide abuse-related details
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral tissue oxygenation (PsqO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parents reading to their child at least 3 days/week
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Appendicular Skeletal Muscle (ASM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean area under the plasma concentration‐time curve (AUC(0‐infinity)) of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak plasma concentration of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination half-life of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glomerular filtration rate decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: albuminuria reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean logarithm of the minimal angle of resolution visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximal subretinal fluid height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean central subfield thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to initial pathogen identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BSID-II scores at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of infection related morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability scores for tampons
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: recurrence-free time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: effect on urinary symptoms, including pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Corneal Epithelial Cell Density (ECD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial hyperplasia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: composite of defined cardiovascular and cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sputum smear conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Success rate of ultrasound-guided puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts required for puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cross-sectional area of the artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total recuperation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes